摘要
目的:观察乌司他丁对食管癌患者术中、术后细胞免疫功能的影响。方法:选择食管癌患者30例,ASAⅠ-Ⅱ级,随机分为对照组(A组,n=15)和乌司他丁治疗组(B组,n=15)。B组于麻醉诱导完成后、切皮前将乌司他丁20万U溶于生理盐水20ml缓慢静脉推注,若手术时间>2h,则追加1次。A组注入等量生理盐水。两组均于入室麻醉前(0d),术后第1天(1d),术后第3天(3d),术后第7天(7d)空腹状态下抽取静脉血2ml,肝素抗凝,流式细胞仪测定T细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)含量以及NK细胞。结果:0d:两组间各类细胞含量无明显差异;1d:A、B组CD4+、NK细胞含量,CD4+/CD8+比值均下降,CD8+细胞含量则无明显变化;3d:细胞异常分布开始逐渐恢复,B组基本恢复到术前水平,快于A组;7d:A组各类细胞恢复至术前水平,B组CD4+、CD4+/CD8+、较术前均有显著升高。结论:乌司他丁能够促进食管癌患者术后T细胞亚群的恢复,对患者的细胞免疫具有保护作用。
Objective： To explore the effects of ulinastatin on T- lymphocyte subgroups during esophagectomy. Methods：Thirty patients with esophageal carcinoma were randomly divided into the group A as control （without ulinastatin, n = 15） and group B （with ulinastatin, n = 15）. After induction of anesthesia, ulinastatin with 20ml physiological saline was intravenously injected slowly in group B, and the same dosage was repeated if the operation was longer than 2h ,20ml physiological saline was administrated in group A. The blood sample was taken from both groups at the following time ：0d （before anesthesia）, 1 d （the first postoperative day） ,3 d （the third postoperative day） ,7d （the seventh postoperative day）. The content of T lymphocyte subgroups （ CD3^＋ , CD4^＋ , CD8^ ＋ , CD4 ^＋/CD8^＋ ） and NK ceils were measured by flow cytometry. Results：There were no significant differences in the content of lymphocyte subgroups between the two groups at 0d. The content of CD4^＋ , CD4^＋ / CD8^＋ , and NK was decreased at 1 d, except CD8^＋. They were back to the level of 0d in group B at 3d. However, the number of these T - lymphocyte subgroups was back to the level of 0d in group A till 7d,and the content in group B was significantly higher than that in group A. Conclusion： Ulinastatin can promote T - lymphocyte subgroups restorage in patients after esophagectomy for esophageal carcinoma. Ulinastatin may protect the patient＇s celluar immune function from damage of surgery.
出处
《现代肿瘤医学》
CAS
2009年第10期1887-1889,共3页
Journal of Modern Oncology
关键词
食管癌
乌司他丁
细胞免疫
esophageal carcinoma
ulinastatin
cellular immunity
